Skip To Main Content
Lohitash Karumbaiah on Muck Rack

Lohitash Karumbaiah

As seen in: Frontiers, Mary Ann Liebert, Inc., Cell & Gene
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lohitash

Contact Lohitash, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

06.04.22 -- Oligonucleotides: Regulations & Quality Standards

|
By Lohitash Karumbaiah, Sarita Acharya, Christian Zeine, Mitchell Gonzales
| Cell & Gene Verified
Get more Cell & Gene insight with our FREE newsletter sign me up Discovery Trials Regulatory Outsourcing Commercialization Newsletter | June 4, 2022 By Lohitash Karumbaiah, Ph.D., Regenerative Bioscience Center, University of Georgia By Sarita K. Acharya and Christian Zeine, U.S. Pharmacopeia (USP) By Abdul Ally and Amy Hendricks This website uses cookies to ensure you get the best experience on our website. Learn more
Open in Who Shared Issue with article?

05.31.22 -- Oligonucleotides: Regulations & Quality Standards

|
By Sarita Acharya, Christian Zeine, Lohitash Karumbaiah, Mitchell Gonzales
| Cell & Gene Verified
By Sarita K. Acharya and Christian Zeine, U.S. Pharmacopeia (USP) Oligonucleotides are promising therapeutic agents to treat diseases such as neurodegenerative disorders, cancer, and more. This article recaps a recent USP workshop where participants from regulatory agencies, industry, and academia gathered to discuss best practices.
Open in Who Shared Issue with article?

02.08.22 -- The Value Of Bioelectronic Assays In Cancer Therapy Development

|
By Lohitash Karumbaiah, Erin Harris Verified, Joe Cintavey, Meghan Meeuwissen
| Cell & Gene Verified
By Lohitash Karumbaiah, Ph.D., University of Georgia This article explains the value of bioelectronic assays in cancer therapy development. By Erin Harris, editor in chief, Cell & Gene Ken Drazan, M.D., cofounder, chairman, and CEO at ArsenalBio, explains how the company explores the use of computational biology to destroy cancer cells in solid tumors.
Open in Who Shared Issue with article?
See all 6 articles